ACRP CCRC® Certification Mastery:
Exam-Style Questions with Evidence-
Based Rationales Covering All 6
Content Domains
Scientific Concepts and Research Design
1. Which phase of a clinical trial is primarily designed to assess the
therapeutic efficacy of a drug in patients with the target condition?
A) Phase I
B) Phase II
C) Phase III
D) Phase IV
Answer: B
Rationale: Phase II trials are the first to study the drug in patients with the
target condition. Their primary objective is to explore therapeutic efficacy,
determine dose ranges for Phase III, and further characterize safety.
2. Phase I clinical trials typically have which of the following
characteristics?
A) Large numbers of subjects with the target disease
, B) Small numbers of subjects (often healthy volunteers) and a focus on
tolerability and pharmacokinetics
C) Post-marketing surveillance
D) A focus on comparing the new drug to the current standard of care
Answer: B
Rationale: Phase I trials are the first in humans, typically enrolling small
numbers (20-80) of healthy volunteers (or patients for oncology). They
focus on safety, tolerability, pharmacokinetics, and dose escalation to
determine the Maximum Tolerated Dose (MTD).
3. The first trial in humans of a novel anti-tumor compound that has
completed animal testing would MOST likely involve:
A) Healthy volunteers and a placebo control
B) Pharmacokinetic analysis and dose escalation
C) A large, multi-center efficacy trial
D) Healthy volunteers and dose escalation
Answer: B
Rationale: For oncology compounds, Phase I trials typically involve patients
with the disease rather than healthy volunteers. The focus remains on
pharmacokinetic analysis, safety, and dose escalation to establish the MTD.
4. Which document describes the objective(s), design, methodology,
statistical considerations, and organization of a clinical trial?
A) Investigator's Brochure
B) Clinical study protocol
C) Clinical study report
D) Subject information sheet
,Answer: B
Rationale: The clinical study protocol is the document that describes the
objective(s), design, methodology, statistical considerations, and
organization of a clinical trial. It is the blueprint for the study.
5. The concept of tachyphylaxis refers to:
A) A gradual decrease in drug effect over time
B) A rapid decrease in drug effectiveness after repeated administration
C) An increase in drug effect over time
D) A complete lack of drug effect from the first dose
Answer: B
Rationale: Tachyphylaxis is a rapid, acute decrease in response to a drug
after repeated administration over a short period. This differs from
tolerance, which is a gradual decrease in effect over longer periods.
6. A study design where neither the subject nor the investigator knows
the treatment assignment is called:
A) Open-label
B) Single-blind
C) Double-blind
D) Crossover
Answer: C
Rationale: A double-blind design prevents bias by keeping both the
subject and investigator unaware of treatment assignments. This is
considered the gold standard for clinical trials.
7. The primary purpose of randomization in a clinical trial is to:
, A) Reduce the number of subjects needed
B) Eliminate the need for a control group
C) Minimize selection bias and balance known and unknown
confounding factors
D) Ensure every subject receives active treatment
Answer: C
Rationale: Randomization minimizes selection bias and helps balance both
known and unknown confounding factors between treatment groups,
making groups comparable at baseline.
8. The clinical study report (CSR) is a document that:
A) Is written by the CRC to summarize subject visits
B) Is a written description of the entire clinical trial, including the
methods, results, and conclusions
C) Is the same as the protocol
D) Is only required for Phase III trials
Answer: B
Rationale: The Clinical Study Report (CSR) is a comprehensive, integrated
report on a clinical trial of any therapeutic, prophylactic, or diagnostic agent
conducted in human subjects. It includes a full description of the methods,
results, and conclusions.
9. The investigator's signature page on the protocol indicates that the
investigator:
A) Owns the data generated at the site
B) Agrees to the protocol's content and will conduct the study in
accordance with GCP
C) Has completed financial disclosure forms
Exam-Style Questions with Evidence-
Based Rationales Covering All 6
Content Domains
Scientific Concepts and Research Design
1. Which phase of a clinical trial is primarily designed to assess the
therapeutic efficacy of a drug in patients with the target condition?
A) Phase I
B) Phase II
C) Phase III
D) Phase IV
Answer: B
Rationale: Phase II trials are the first to study the drug in patients with the
target condition. Their primary objective is to explore therapeutic efficacy,
determine dose ranges for Phase III, and further characterize safety.
2. Phase I clinical trials typically have which of the following
characteristics?
A) Large numbers of subjects with the target disease
, B) Small numbers of subjects (often healthy volunteers) and a focus on
tolerability and pharmacokinetics
C) Post-marketing surveillance
D) A focus on comparing the new drug to the current standard of care
Answer: B
Rationale: Phase I trials are the first in humans, typically enrolling small
numbers (20-80) of healthy volunteers (or patients for oncology). They
focus on safety, tolerability, pharmacokinetics, and dose escalation to
determine the Maximum Tolerated Dose (MTD).
3. The first trial in humans of a novel anti-tumor compound that has
completed animal testing would MOST likely involve:
A) Healthy volunteers and a placebo control
B) Pharmacokinetic analysis and dose escalation
C) A large, multi-center efficacy trial
D) Healthy volunteers and dose escalation
Answer: B
Rationale: For oncology compounds, Phase I trials typically involve patients
with the disease rather than healthy volunteers. The focus remains on
pharmacokinetic analysis, safety, and dose escalation to establish the MTD.
4. Which document describes the objective(s), design, methodology,
statistical considerations, and organization of a clinical trial?
A) Investigator's Brochure
B) Clinical study protocol
C) Clinical study report
D) Subject information sheet
,Answer: B
Rationale: The clinical study protocol is the document that describes the
objective(s), design, methodology, statistical considerations, and
organization of a clinical trial. It is the blueprint for the study.
5. The concept of tachyphylaxis refers to:
A) A gradual decrease in drug effect over time
B) A rapid decrease in drug effectiveness after repeated administration
C) An increase in drug effect over time
D) A complete lack of drug effect from the first dose
Answer: B
Rationale: Tachyphylaxis is a rapid, acute decrease in response to a drug
after repeated administration over a short period. This differs from
tolerance, which is a gradual decrease in effect over longer periods.
6. A study design where neither the subject nor the investigator knows
the treatment assignment is called:
A) Open-label
B) Single-blind
C) Double-blind
D) Crossover
Answer: C
Rationale: A double-blind design prevents bias by keeping both the
subject and investigator unaware of treatment assignments. This is
considered the gold standard for clinical trials.
7. The primary purpose of randomization in a clinical trial is to:
, A) Reduce the number of subjects needed
B) Eliminate the need for a control group
C) Minimize selection bias and balance known and unknown
confounding factors
D) Ensure every subject receives active treatment
Answer: C
Rationale: Randomization minimizes selection bias and helps balance both
known and unknown confounding factors between treatment groups,
making groups comparable at baseline.
8. The clinical study report (CSR) is a document that:
A) Is written by the CRC to summarize subject visits
B) Is a written description of the entire clinical trial, including the
methods, results, and conclusions
C) Is the same as the protocol
D) Is only required for Phase III trials
Answer: B
Rationale: The Clinical Study Report (CSR) is a comprehensive, integrated
report on a clinical trial of any therapeutic, prophylactic, or diagnostic agent
conducted in human subjects. It includes a full description of the methods,
results, and conclusions.
9. The investigator's signature page on the protocol indicates that the
investigator:
A) Owns the data generated at the site
B) Agrees to the protocol's content and will conduct the study in
accordance with GCP
C) Has completed financial disclosure forms
